Evidence map›Paper›PMID 38725218›Full record

ReviewMolecular carcinogenesis2024

Deciphering CD4

Catherine Kirkpatrick, Yong-Chen William Lu

Abstract readReview
In one paragraph

Review in Molecular carcinogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Catherine KirkpatrickDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0009-0000-4955-2410
Yong-Chen William LuDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0002-0275-9825

Funding

Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-RenewalR01CA143130 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAKAGAWA, MAYUMI · 2010 to 2025
$10.0M
Institutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3M
Arkansas Breast Cancer Research ProgramNCATS NIH HHS KL2 TR003108NCATS NIH HHS UL1 TR003107NCI NIH HHS R01 CA143130NIH HHS R01CA143130Translational Research Institute, University of Arkansas for Medical Sciences KL2TR003108Translational Research Institute, University of Arkansas for Medical Sciences UL1TR003107Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
6 · The paper itself

Abstract

It's been long thought that CD8

Indexed as

CD4-Positive T-LymphocytesImmunotherapyNeoplasmsAnimalsCD8-Positive T-LymphocytesHumanscancer immunotherapyCD4T celltumor microenvironment

Identifiers

PMID38725218
PMCPMC11166516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.